补体与移植：从新机制到潜在生物标志物及新型治疗策略
Complement and Transplantation: From New Mechanisms to Potential Biomarkers and Novel Treatment Strategies.
作者信息
Horwitz Julian K, Chun Nicholas H, Heeger Peter S
机构信息
Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA; Department of Surgery, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA.
Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA.
出版信息
Clin Lab Med. 2019 Mar;39(1):31-43. doi: 10.1016/j.cll.2018.10.004. Epub 2018 Dec 20.
Abstract
The complement system, traditionally considered a component of innate immunity, is now recognized as a crucial mediator of the adaptive immune response in solid organ transplantation. Preclinical and early human trials have demonstrated the importance of complement effector mechanisms in driving allograft injury during specific antigraft immune responses, including ischemia-reperfusion injury, T-cell-mediated rejection, and antibody-mediated rejection, as well as a potential role for complement-derived risk stratification biomarkers. These data support the need for further testing of complement inhibitors in solid organ transplant recipients.
摘要
补体系统传统上被认为是固有免疫的一个组成部分，现在被公认为实体器官移植中适应性免疫反应的关键调节因子。临床前和早期人体试验已经证明，在特定的抗移植免疫反应中，补体效应机制在驱动同种异体移植物损伤方面具有重要作用，包括缺血再灌注损伤、T细胞介导的排斥反应和抗体介导的排斥反应，以及补体衍生的风险分层生物标志物的潜在作用。这些数据支持在实体器官移植受者中进一步测试补体抑制剂的必要性。
相似文献
1
Complement and Transplantation: From New Mechanisms to Potential Biomarkers and Novel Treatment Strategies.补体与移植：从新机制到潜在生物标志物及新型治疗策略
Clin Lab Med. 2019 Mar;39(1):31-43. doi: 10.1016/j.cll.2018.10.004. Epub 2018 Dec 20.
2
The Role of Complement in Organ Transplantation.补体在器官移植中的作用。
Front Immunol. 2019 Oct 4;10:2380. doi: 10.3389/fimmu.2019.02380. eCollection 2019.
3
Molecules Great and Small: The Complement System.或大或小的分子：补体系统
Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1636-50. doi: 10.2215/CJN.06230614. Epub 2015 Jan 7.
4
Role of complement and perspectives for intervention in transplantation.补体在移植中的作用及干预策略。
Immunobiology. 2013 May;218(5):817-27. doi: 10.1016/j.imbio.2012.09.002. Epub 2012 Oct 4.
5
[Sterile inflammatory response to ischemia-reperfusion injury: immediate and long term consequences on graft function].[对缺血再灌注损伤的无菌性炎症反应：对移植物功能的即时和长期影响]
Bull Acad Natl Med. 2011 Apr-May;195(4-5):847-59; discussion 859.
6
Control of innate immunological mechanisms as a route to drug minimization.控制先天免疫机制作为减少药物使用的途径。
Curr Opin Organ Transplant. 2014 Aug;19(4):342-7. doi: 10.1097/MOT.0000000000000094.
7
The Role of Complement in Liver Injury, Regeneration, and Transplantation.补体在肝损伤、再生和移植中的作用。
Hepatology. 2019 Aug;70(2):725-736. doi: 10.1002/hep.30508. Epub 2019 Jul 15.
8
Role of the complement system in rejection.补体系统在排斥反应中的作用。
Curr Opin Immunol. 2003 Oct;15(5):487-92. doi: 10.1016/s0952-7915(03)00100-6.
9
Innate immunity-mediated allograft rejection and strategies to prevent it.先天性免疫介导的同种异体移植排斥反应及其预防策略。
Transplant Proc. 2007 Apr;39(3):667-72. doi: 10.1016/j.transproceed.2007.01.052.
10
Complement system in lung transplantation.补体系统在肺移植中的作用。
Clin Transplant. 2018 Apr;32(4):e13208. doi: 10.1111/ctr.13208. Epub 2018 Feb 14.
引用本文的文献
1
"Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.依库珠单抗优先用于移植后血栓性微血管病的管理
Kidney Int Rep. 2024 Jan 10;9(4):982-993. doi: 10.1016/j.ekir.2024.01.013. eCollection 2024 Apr.
2
Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT).肝移植肿瘤学中的免疫抑制：意大利肝移植专家委员会（I-BELT）立场文件。
Updates Surg. 2024 Jun;76(3):725-741. doi: 10.1007/s13304-024-01845-z. Epub 2024 May 7.
3
Critical Role of CD55 in Controlling Wound Healing.CD55在控制伤口愈合中的关键作用。
J Immunol. 2024 Apr 1;212(7):1142-1149. doi: 10.4049/jimmunol.2300628.
4
Complement, complosome, and complotype: A perspective.补体、补体复合物和补体型：一种观点。
Eur J Immunol. 2023 Dec;53(12):e2250042. doi: 10.1002/eji.202250042. Epub 2023 May 11.
5
Complement-targeted therapies in kidney transplantation-insights from preclinical studies.补体靶向治疗在肾移植中的研究进展。
Front Immunol. 2022 Oct 13;13:984090. doi: 10.3389/fimmu.2022.984090. eCollection 2022.
6
Iguratimod Attenuates Macrophage Polarization and Antibody-Mediated Rejection After Renal Transplant by Regulating KLF4.艾拉莫德通过调控KLF4减轻肾移植后巨噬细胞极化和抗体介导的排斥反应。
Front Pharmacol. 2022 May 9;13:865363. doi: 10.3389/fphar.2022.865363. eCollection 2022.
7
The Evaluation and Validation of Blood-Derived Novel Biomarkers for Precise and Rapid Diagnosis of Tuberculosis in Areas With High-TB Burden.在结核病高负担地区用于结核病精准快速诊断的血液源性新型生物标志物的评估与验证
Front Microbiol. 2021 Jun 14;12:650567. doi: 10.3389/fmicb.2021.650567. eCollection 2021.
8
More than a Pore: Nonlytic Antimicrobial Functions of Complement and Bacterial Strategies for Evasion.不止一个孔：补体的非裂解性抗菌功能和细菌逃避的策略。
Microbiol Mol Biol Rev. 2021 Jan 27;85(1). doi: 10.1128/MMBR.00177-20. Print 2021 Feb 17.
9
A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury.一种新型损伤部位-天然抗体靶向补体抑制剂可预防肺移植损伤。
Am J Transplant. 2021 Jun;21(6):2067-2078. doi: 10.1111/ajt.16404. Epub 2021 Feb 26.
10
Sterile inflammation in thoracic transplantation.胸移植中的无菌性炎症。
Cell Mol Life Sci. 2021 Jan;78(2):581-601. doi: 10.1007/s00018-020-03615-7. Epub 2020 Aug 17.
本文引用的文献
1
Association Between Promoter Polymorphisms in CD46 and CD59 in Kidney Donors and Transplant Outcome.供体肾组织中 CD46 和 CD59 启动子多态性与移植结局的关系。
Front Immunol. 2018 May 14;9:972. doi: 10.3389/fimmu.2018.00972. eCollection 2018.
2
A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.一项 I/II 期、双盲、安慰剂对照研究，评估 C1 酯酶抑制剂预防尸体供肾移植受者延迟肾功能恢复的安全性和有效性。
Am J Transplant. 2018 Dec;18(12):2955-2964. doi: 10.1111/ajt.14767. Epub 2018 May 14.
3
Donor pretreatment with nebulized complement C3a receptor antagonist mitigates brain-death induced immunological injury post-lung transplant.供体预处理联合雾化补体 C3a 受体拮抗剂减轻肺移植后脑死亡诱导的免疫损伤。
Am J Transplant. 2018 Oct;18(10):2417-2428. doi: 10.1111/ajt.14717. Epub 2018 Apr 10.
4
Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation.活体供肝移植后急性细胞排斥反应患者循环免疫复合物中抗原的免疫复合物组分析
Transpl Immunol. 2018 Jun;48:60-64. doi: 10.1016/j.trim.2018.02.011. Epub 2018 Mar 2.
5
T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (T) Generation and T-Dependent Cardiac Allograft Survival.C5a 受体 2 在 T 细胞上的表达增强了小鼠调节性 T 细胞（T）的生成和 T 细胞依赖性心脏移植物的存活。
J Immunol. 2018 Mar 15;200(6):2186-2198. doi: 10.4049/jimmunol.1701638. Epub 2018 Feb 7.
6
Impact of complement component 3/4/5 single nucleotide polymorphisms on renal transplant recipients with antibody-mediated rejection.补体成分3/4/5单核苷酸多态性对抗体介导排斥反应的肾移植受者的影响。
Oncotarget. 2017 Oct 10;8(55):94539-94553. doi: 10.18632/oncotarget.21788. eCollection 2017 Nov 7.
7
Complement Recognition Pathways in Renal Transplantation.肾移植中的补体识别途径
J Am Soc Nephrol. 2017 Sep;28(9):2571-2578. doi: 10.1681/ASN.2017010079. Epub 2017 Jun 29.
8
A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.米罗西普（APT070）预防同种异体肾移植缺血再灌注损伤疗效的双盲随机对照研究（EMPIRIKAL）：一项随机对照试验的研究方案
Trials. 2017 Jun 6;18(1):255. doi: 10.1186/s13063-017-1972-x.
9
TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement.Toll样受体诱导的小鼠树突状细胞（DC）激活需要DC内源性补体。
J Immunol. 2017 Jul 1;199(1):278-291. doi: 10.4049/jimmunol.1700339. Epub 2017 May 24.
10
Complement Dependence of Murine Costimulatory Blockade-Resistant Cellular Cardiac Allograft Rejection.补体依赖性的小鼠共刺激阻断耐药性的细胞性心脏移植物排斥反应。
Am J Transplant. 2017 Nov;17(11):2810-2819. doi: 10.1111/ajt.14328. Epub 2017 May 30.
Zotero 插件